We're sorry but this app doesn't work properly without JavaScript enabled. Please enable it to continue. Epic Investment Partners Views: The Week Ahead - MeDirect

Picture your Future. Save for it by earning 1.5% on a 1-year Term Deposit Account! Learn more.

Epic Investment Partners Views: The Week Ahead

Today we have Eurozone CPI, and we will hear from the Fed’s Bostic, Logan, Jefferson and Williams. With little in the way of key data, on Tuesday we have the opening of the Qatar Economic Forum (Tue-Thu), and a gathering of G-7 ministers and central bank governors. Central bank guidance includes the Fed’s Bostic, Daly, Hammack, and Musalem, the ECB’s Wunsch and Knot, and the BoE’s Pill. UK CPI will draw market attention on Wednesday, and we will hear from the ECBVs Guindos on the central bank’s financial stability review, and Lane discusses negative interest rates. A raft of manufacturing and services PMI readings are due on Thursday, and in the US we have jobless claims and existing home sales figures. Central bank chatter includes the ECB’s Vujcic, Holzmann and Pill, the Fed’s Williams and the BoE’s Breedan and Dhingra. Germany GDP, Japan CPI and US new home sales and building permits data feature on Friday and the ECB’s Pill lectures on “inflation and disinflation in the euro area” 

Markets witnessed a calm start to last week amid progress in US-China trade discussions. The softer-than-expected US CPI and PPI figures supported market sentiment, albeit with limited tariff impact in April. The retail sales figures broadly surprised to the downside, while the retail sales control group reading, considered a more accurate gauge of consumer spending and monitored by the Fed, fell 0.2%, against expectations for a 0.3% rise. We heard from a number of Fed members who maintained the wait-and-see/patience approach. Then on Friday Moody’s downgraded the US’s credit rating by one notch to Aa1 bringing it in-line with S&P and Fitch’s AA ratings. Moody’s cited the ballooning debts and consequent high interest payments, and limited effort by the government to improve the fiscal position, saying it expected the US’s federal debt burden will rise to ~134% of GDP by 2035. The rating agency also noted that Trump tariffs will significantly hurt the nation’s long-term growth.  

The reports unsettled markets with the yield on the 10-year rising 10bps to 4.48%, while the 30-year rose 11bps to 4.95%, and is currently trading through 5% this morning. Meanwhile, the S&P Index enjoyed a 5.27% rally last week, and the dollar gained 0.75%. Brent crude rose 2.35%, closing the week at $65.4 pb amid easing US-China trade tensions.  

Over in China, data released this morning was mixed. Retail sales missed expectations, gaining 5.1%yoy while industrial production surprised to the upside gaining 6.1% in April. The property market remained weak despite government stimulus efforts including reduced mortgage costs. China’s home prices remained relatively flat in April – the 24th consecutive month without growth since May 2023. Year-over-year prices fell 4.0%, with property investment dropping 10.3% as the real estate sector continues its prolonged slump. 


Epic Investment Partner’s Key risks & Disclaimers:

EPIC Global Equity Fund (the “Fund”) is a sub-fund of EPIC Funds p.l.c. (the “Company”), which is an open-ended umbrella fund authorised in Ireland as a UCITS fund and regulated by the Central Bank of Ireland. This marketing material has been approved in the UK by EPIC Markets (UK) LLP, trading as EPIC Investment Partners, which is a limited liability partnership incorporated and registered in England and Wales under partnership OC306260 with its registered office at Audrey House, 16-20 Ely Place, London EC1N 6SN. EPIC Markets (UK) LLP is regulated by the Financial Conduct Authority. Distribution of this material and the offer of the Fund are specifically restricted in certain jurisdictions. In particular, but without limitation, neither this material nor shares in the Fund are available to US persons.

This document is for general information purposes only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. It is not a personal recommendation and it should not be regarded as a solicitation or an offer to buy or sell any shares in the Fund. This document represents the views of EPIC Investment Partners at the time of writing. It should not be construed as investment advice. Any person interested in investing in the Fund should conduct their own investigation and analysis of the Fund and should consult their own professional tax, accounting or other advisers as to the risks involved in making such an investment. Full details of the Fund’s investment objectives, investment policy and risks are set out in the Fund’s Prospectus and Supplement which, together with the Key Information Document (“KID”), are available on request and free of charge from Maples Fund Services (Ireland) Limited, 32 Molesworth Street, Dublin 2, Ireland and, in the UK, from EPIC Markets (UK) LLP, Audrey House, 16-20 Ely Place, London EC1N 6SN. Any offering of the Fund is only made on the terms of the current Prospectus, Supplement and KID. A subscription in the Fund can only be made after the provision of the KIID and should be made solely upon the information contained in the Prospectus, Supplement and KID.

An investment in the Fund is not suitable for an investor who cannot sustain a loss on their investment. There is no guarantee of the Fund’s future performance and past performance is not a reliable indicator of future performance. The value of your investment and the income derived from it can go down as well as up, and you may not get back the money you invested. The risks associated with making an investment in the Fund are described in the Prospectus and Supplement but investors should note, in particular, the following: 1) Foreign currency denominated investments are subject to fluctuations in exchange rates that could have a positive or an adverse effect on an investor’s returns. There is also a risk that currency hedging transactions for one share class may in extreme cases adversely affect the net asset value of the other share classes within the same sub-fund since there is no legal segregation between share classes; 2) The Fund is subject to the risk of the insolvency of its counterparties; and 3) Emerging market securities are subject to greater social, political, regulatory, and currency risks than developed market securities. This may impact the liquidity and value of such securities and, consequently, the value of the Fund.


MeDirect Disclaimers:

This information has been accurately reproduced, as received from EPIC Investment Partners. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document is intended for retail clients however, it may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Information Document (KID), which may be obtained from MeDirect Bank (Malta) plc.

Join MeDirect today to access the tools you need to put your money to work on your own terms.

Latest news articles

Bonds and Shares

Malta Government Stocks – July 2025

MeDirect will be accepting applications from anyone interested in applying for the July 2025 issues of Malta Government Stocks.

Time to be more tactical
All News

BlackRock Commentary: Time to be more tactical

Despite major policy shifts, we believe structural limits on trade and debt, along with transformative forces like AI, support a risk-on stance and an overweight in U.S. equities, as outlined in BlackRock’s 2025 Midyear Outlook.

Experience better Banking

The sooner you start managing your money, your way, using the best-in-class tools, the sooner you’ll see results. 


Sign up and open your account for free, within minutes.

MeDirect_Multi-Devices-cards

You are leaving medirect.com.mt

Please be aware that the external site policies, or those of another MeDirect website, may differ from this website’s terms and conditions and privacy policy. The next website will open in a new browser window or tab.

 

Note: MeDirect is not responsible for any content on third party sites, nor does a link suggest endorsement of those sites and/or their content.

Login

We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.